On the third HRSO Act review of a continuing detention order, the Court found the respondent remained a high risk serious offender but rescinded the CDO and imposed a supervision order. The critical factual change was the respondent's informed consent to take hormonal anti-libidinal medication (Androcur), which expert evidence indicated reduces reoffending rates from 85% to 5%, combined with the ability to monitor compliance through blood testing. The Court accepted expert consensus that the respondent had reached treatment saturation in custody and that no further gains were achievable without community release, and held that the extensive supervision conditions — including anti-libidinal medication, electronic monitoring, curfew, alcohol testing, and restrictions on contact with females — reduced the risk to a level that was reasonably acceptable and ensured adequate community protection.
The full text is available to signed-in members, including the 1 later case that cites this judgment.